ArticleCancer immunology, immunotherapy : CII2025
Exploration of the benefits and resistance mechanisms of immunotherapy based on PD-L1 expression, circulating tumor DNA and T-cell receptor profiles in advanced gastric cancer.
Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCombination regimens of immunotherapy and chemotherapy have become the standard treatment for HER2-negative advanced gastric cancer (AGC). Here, we evaluate the therapeutic efficacy of first-line treatment regimens across different PD-L1 expression, circulating tumor DNA (ctDNA) and T-cell receptor (TCR).
methodsThis study retrospectively recruited 245 patients with AGC. 55 blood samples from 20 patients were prospectively collected before immunotherapy, after two cycles of treatment, and during disease progression.
resultsIn the CPS < 5 cohort, chemotherapy + PD-1 inhibitor + anti-angiogenic treatment showed a higher progression-free survival (PFS). In the CPS ≥ 5 cohort, chemotherapy + PD-1 inhibitor improved median PFS (p = 0.04) and ORR (p = 0.014) over chemotherapy alone. ctDNA analysis revealed that at various time points, patients in the short-PFS group exhibited significantly elevated maxVAF and ctDNA levels. Post-treatment, ctDNA levels decreased in 50% of patients in the long-PFS group, whereas only 25% in the short-PFS group. The short-PFS group had a lower TCR clone count, while no significantly different in the diversity of the TCR repertoire compared with long-PFS groups.
conclusionsThese findings suggest the different efficacy of first-line treatment regimens across varying levels of PD-L1 expression, and the molecular characteristics of patients with long-term benefits from immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.